10x Genomics (TXG) Depreciation & Amortization (CF) (2018 - 2026)

10x Genomics has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $10.0 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $10.0 million, up 24.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $38.1 million (up 9.87% YoY), and the FY2025 annual result was $36.2 million, up 0.89% from the prior year.
• Depreciation & Amortization (CF) came in at $10.0 million for Q1 2026 at 10x Genomics, down from $10.1 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.3 million in Q3 2025 to a low of $6.2 million in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $9.0 million (2024), against an average of $8.4 million.
• Across the five-year window, Depreciation & Amortization (CF) surged 52.94% in 2023 and decreased 12.89% in 2025, its largest moves.
• 10x Genomics' Depreciation & Amortization (CF) stood at $6.5 million in 2022, then jumped by 49.01% to $9.7 million in 2023, then decreased by 9.95% to $8.8 million in 2024, then grew by 15.03% to $10.1 million in 2025, then slipped by 1.07% to $10.0 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $10.0 million (Q1 2026), $10.1 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.